PiRNA-Hsap_1847317 may serve as a novel biomarker of PD-1 inhibitor resistance in patients with advanced non-small cell lung cancer.
6 affiliations
- 1Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
- 2Department of Urology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
- 3Department of Radiation Oncology, Guiqian International General Hospital, Guiyang, China.
- 4School of Public Health, Zunyi Medical University, Zunyi, Guizhou, China.
- 5Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China. Electronic address: [email protected].
- 6Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China. Electronic address: [email protected].
Abstract
Background
Acquired resistance to programmed cell death protein 1 (PD-1) inhibitors presents a major clinical challenge in the treatment of non-small cell lung cancer (NSCLC). This study aims to elucidate the epigenetic mechanisms underlying PD-1 inhibitor resistance, with a specific focus on the expression profiles of PIWI-interacting RNAs (piRNAs) and their associated signaling networks.Methods
High-throughput RNA sequencing was performed on matched pre- and post-resistance plasma samples from three NSCLC patients to identify differentially expressed piRNAs. The top five candidate piRNAs were selected for subsequent verification. Plasma piRNA levels and comprehensive clinical data from an independent cohort of 50 NSCLC patients (evaluated at both pre- and post-resistance stages) were analyzed. Downstream target genes of the candidate piRNAs were predicted using TargetScan and miRanda algorithms, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses. Target gene expression was experimentally validated via quantitative real-time PCR (qRT-PCR). Spearman's rank correlation was utilized to assess the relationship between piRNA expression and systemic inflammatory indices. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves.Results
Five candidate piRNAs (Hsap_2765751, Hsap_249, Hsap_1847317, Hsap_681799, and Hsap_857420) exhibited significant differential expression. Notably, Hsap_1847317 was robustly upregulated following the development of resistance (P < 0.001). Bioinformatic and experimental analyses implicated Hsap_1847317 is implicated in the Wnt signaling pathway, while qRT-PCR demonstrated significantly higher AXIN2 mRNA expression after resistance (P < 0.001). these associative data do not establish direct regulation. Furthermore, the systemic neutrophil-to-lymphocyte ratio (NLR) significantly increased during the resistance phase (P < 0.001) and exhibited a positive correlation with Hsap_1847317 expression (r = 0.395, P = 0.005). ROC curve analysis demonstrated excellent predictive efficacy, yielding an area under the curve (AUC) of 0.944 for Hsap_1847317 and 0.720 for NLR in this cohort.Conclusion
Our findings indicate that plasma Hsap_1847317 and NLR are candidate non-invasive biomarkers for monitoring acquired resistance to PD-1 inhibitors in NSCLC. This study association between Hsap_1847317, Wnt-related enrichment, and AXIN2 mRNA provides a hypothesis for further mechanistic testing rather than evidence of a causal Hsap_1847317/Wnt/AXIN2 axis.
Related
- The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
- Cardiovascular biomarker phenotype associated with immune checkpoint inhibitor therapy in patients with non-small cell lung cancer: an exploratory blood transcriptome study
- A Multi-Kinase Inhibitor Screen Identifies mTOR Signaling as a Vulnerability in Advanced Prostate Cancer.
- Barriers to Biomarker-Guided Advanced Breast Cancer Care in India: Diagnostic, Economic, and Implementation Challenges
- Case Report: Immune checkpoint inhibitor–induced hypophysitis presenting as acute paralytic ileus mimicking mechanical bowel obstruction in a patient affected by advanced non-small cell lung cancer
BibTeX
@article{meng2026pirnahsap1847317,
title = {{PiRNA-Hsap_1847317 may serve as a novel biomarker of PD-1 inhibitor resistance in patients with advanced non-small cell lung cancer.}},
author = {Mi Meng and Bo Yu and Jie Luo and Heng Sun and Zeming Mo and Sisi He and Hu Ma},
journal = {Translational oncology},
year = {2026},
month = oct,
doi = {10.1016/j.tranon.2026.103071},
url = {https://europepmc.org/article/MED/42874535},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - PiRNA-Hsap_1847317 may serve as a novel biomarker of PD-1 inhibitor resistance in patients with advanced non-small cell lung cancer.
AU - Mi Meng
AU - Bo Yu
AU - Jie Luo
AU - Heng Sun
AU - Zeming Mo
AU - Sisi He
AU - Hu Ma
PY - 2026
DA - 2026/10/14
JO - Translational oncology
DO - 10.1016/j.tranon.2026.103071
UR - https://europepmc.org/article/MED/42874535
AB - Background Acquired resistance to programmed cell death protein 1 (PD-1) inhibitors presents a major clinical challenge in the treatment of non-small cell lung cancer (NSCLC). This study aims to elucidate the epigenetic mechanisms underlying PD-1 inhibitor resistance, with a specific focus on the expression profiles of PIWI-interacting RNAs (piRNAs) and their associated signaling networks.Methods High-throughput RNA sequencing was performed on matched pre- and post-resistance plasma samples from three NSCLC patients to identify differentially expressed piRNAs. The top five candidate piRNAs were selected for subsequent verification. Plasma piRNA levels and comprehensive clinical data from an independent cohort of 50 NSCLC patients (evaluated at both pre- and post-resistance stages) were analyzed. Downstream target genes of the candidate piRNAs were predicted using TargetScan and miRanda algorithms, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses. Target gene expression was experimentally validated via quantitative real-time PCR (qRT-PCR). Spearman's rank correlation was utilized to assess the relationship between piRNA expression and systemic inflammatory indices. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves.Results Five candidate piRNAs (Hsap_2765751, Hsap_249, Hsap_1847317, Hsap_681799, and Hsap_857420) exhibited significant differential expression. Notably, Hsap_1847317 was robustly upregulated following the development of resistance (P < 0.001). Bioinformatic and experimental analyses implicated Hsap_1847317 is implicated in the Wnt signaling pathway, while qRT-PCR demonstrated significantly higher AXIN2 mRNA expression after resistance (P < 0.001). these associative data do not establish direct regulation. Furthermore, the systemic neutrophil-to-lymphocyte ratio (NLR) significantly increased during the resistance phase (P < 0.001) and exhibited a positive correlation with Hsap_1847317 expression (r = 0.395, P = 0.005). ROC curve analysis demonstrated excellent predictive efficacy, yielding an area under the curve (AUC) of 0.944 for Hsap_1847317 and 0.720 for NLR in this cohort.Conclusion Our findings indicate that plasma Hsap_1847317 and NLR are candidate non-invasive biomarkers for monitoring acquired resistance to PD-1 inhibitors in NSCLC. This study association between Hsap_1847317, Wnt-related enrichment, and AXIN2 mRNA provides a hypothesis for further mechanistic testing rather than evidence of a causal Hsap_1847317/Wnt/AXIN2 axis.
SN - 1936-5233
ER -